Skip to main content

Table 2 Reasons of temozolomide or temozolomide plus bevacizumab maintenance therapy discontinuation

From: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

 N = 30
Tumor progression10 (33.3%)
Clinical deterioration without radiological tumor progression9 (30.0%)
Completeion of 12 cycles3 (10.0%)
Complication4 (13.3%)
Changing hospital for palliative care4 (13.3%)